Reaction
Chronic Graft Versus Host Disease In Liver reporting signals
As of the last recalculation, Chronic Graft Versus Host Disease In Liver appears in 355 FAERS reports alongside 22 co-occurring drug terms. The strongest observed disproportionality signal is THIOTEPA (PRR 215.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Thiotepa | 32 | 215.8 | 216.6 |
| Busulfan | 48 | 206.7 | 207.3 |
| Fludarabine Phosphate | 79 | 151.2 | 151.5 |
| Alemtuzumab | 37 | 125.1 | 125.3 |
| Mycophenolate Mofetil | 133 | 91.2 | 91.3 |
| Mycophenolate Mofetil Hydrochloride | 133 | 91.1 | 91.1 |
| Sirolimus | 19 | 87.3 | 87.4 |
| Cyclosporine | 111 | 84.6 | 84.7 |
| Tacrolimus Ointment 0.1% | 112 | 76.6 | 76.6 |
| Tacrolimus Extended-Release Capsules | 112 | 76.4 | 76.4 |
| Tacrolimus | 117 | 64.8 | 64.9 |
| Mycophenilic Acid | 20 | 59.9 | 60.0 |
| Posaconazole Delayed-Release | 9 | 49.3 | 49.3 |
| Melphalan | 18 | 48.8 | 48.9 |
| Atovaquone | 6 | 44.4 | 44.5 |
| Melphalan Hydrochloride | 18 | 44.3 | 44.3 |
| Mycophenolic Acid | 22 | 42.9 | 42.9 |
| Blinatumomab | 7 | 40.1 | 40.1 |
| Posaconazole | 10 | 37.1 | 37.1 |
| Ruxolitinib | 36 | 32.7 | 32.7 |
| Polatuzumab Vedotin | 5 | 30.5 | 30.5 |
| Micafungin Sodium | 4 | 28.0 | 28.0 |